Form 4: CEO Anzalone Sells ARWR Shares for Tax Obligations
Insider Transaction Report
Arrowhead Pharmaceuticals CEO Christopher Anzalone sold shares of common stock on December 17, 2025, to cover tax obligations related to vested performance awards.
Summary
- Christopher Richard Anzalone, the Chief Executive Officer and a Director of Arrowhead Pharmaceuticals, Inc. (ARWR), reported transactions.
- On December 17, 2025, Anzalone disposed of a total of 85,000 shares of common stock through multiple transactions.
- The sales were exclusively conducted to cover anticipated taxes on performance awards that vested on December 12, 2025.
- The shares were sold at weighted average prices ranging from $63.55 to $66.30 per share.
- Following these transactions, Anzalone beneficially owns 3,831,957 shares of common stock, which includes previously reported shares underlying Restricted Stock Units, some of which are still subject to vesting conditions.
Sentiment
Score: 5
Explanation: The transaction is a routine sale of shares by the CEO to cover tax obligations on vested performance awards, which is a common practice and does not indicate a change in company fundamentals or management's outlook.
Future Outlook
NA
Industry Context
This transaction is a routine insider sale, common across all industries, where executives sell a portion of their vested equity awards to cover tax liabilities. It does not reflect specific industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: The sale represents a minor dilution of outstanding shares, but as a tax-related transaction, it is generally not viewed as a negative signal regarding the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 12/12/2025 | Performance awards vested for Christopher Richard Anzalone. |
| 12/17/2025 | Transaction date for the sale of common stock by Christopher Richard Anzalone. |
| 12/19/2025 | Signature date of the Form 4 filing by Christopher Richard Anzalone. |
Recommendation
holdThe filing details a routine insider sale by the CEO to cover tax obligations on vested performance awards. This is a common and expected practice and does not reflect a change in the company's operational performance, strategic direction, or the CEO's confidence in the company. Therefore, it does not provide new information that would alter an existing investment thesis, warranting a 'hold' recommendation.
Keywords
Arrowhead Pharmaceuticals, ARWR, Christopher Anzalone, Insider Transaction, Form 4, Stock Sale, CEO, Director, Tax Obligations, Performance Awards
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.